Conolidine’s analgesic outcomes stem from its conversation with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors in the central nervous process, conolidine modulates alternate molecular targets. A Science Advancements examine uncovered that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://rolimr196suv7.ktwiki.com/user